[{"id":"6e64d8bc-6c09-4f91-9b5f-8fae5114fc10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05003895","created_at":"2021-08-13T13:53:05.789Z","updated_at":"2024-07-02T16:34:38.043Z","phase":"Phase 1","brief_title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT05003895","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"8009476b-712f-4b6f-9467-7f222bfb4fb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05450562","created_at":"2022-07-08T14:55:40.019Z","updated_at":"2024-07-02T16:35:00.176Z","phase":"Phase 1/2","brief_title":"Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05450562","lead_sponsor":"Sanofi","biomarkers":" ALK • GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["ALK • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200"],"overall_status":"Recruiting","enrollment":" Enrollment 106","initiation":"Initiation: 09/20/2022","start_date":" 09/20/2022","primary_txt":" Primary completion: 12/12/2030","primary_completion_date":" 12/12/2030","study_txt":" Completion: 12/12/2030","study_completion_date":" 12/12/2030","last_update_posted":"2024-05-30"},{"id":"2ffdf6d6-d9b4-4d82-87df-b8731e5b67ba","acronym":"ARYA3","url":"https://clinicaltrials.gov/study/NCT04864054","created_at":"2021-04-28T12:52:53.604Z","updated_at":"2024-07-02T16:35:05.862Z","phase":"Phase 2","brief_title":"T-Cell Therapy (ECT204) in Adults With Advanced HCC","source_id_and_acronym":"NCT04864054 - ARYA3","lead_sponsor":"Eureka Therapeutics Inc.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Stivarga (regorafenib) • ECT204"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/11/2022","start_date":" 03/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-06"},{"id":"88f5020d-8814-488d-b3cb-c97d3b33e81f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155189","created_at":"2021-12-13T14:12:43.066Z","updated_at":"2024-07-02T16:35:11.399Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05155189","lead_sponsor":"Zhejiang University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AZD7003"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2024-04-04"},{"id":"f07104db-d6a9-438c-a618-ef3832fea178","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652920","created_at":"2022-12-15T14:58:23.337Z","updated_at":"2024-07-02T16:35:11.688Z","phase":"Phase 1/2","brief_title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","source_id_and_acronym":"NCT05652920","lead_sponsor":"OriCell Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ori-C101"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-03"},{"id":"159f03cc-8156-48bf-876e-731616d2716a","acronym":"DUET-1","url":"https://clinicaltrials.gov/study/NCT05120271","created_at":"2021-11-15T12:53:36.567Z","updated_at":"2024-07-02T16:35:23.821Z","phase":"Phase 1/2","brief_title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","source_id_and_acronym":"NCT05120271 - DUET-1","lead_sponsor":"Sotio Biotech Inc.","biomarkers":" EGFR • ALK • BRCA • GPC3","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression","tags":["EGFR • ALK • BRCA • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BOXR1030"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 12/01/2041","study_completion_date":" 12/01/2041","last_update_posted":"2024-01-11"},{"id":"50719c7c-1135-486c-b135-71ad28c7d4ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04405778","created_at":"2021-01-19T19:50:10.388Z","updated_at":"2024-07-02T16:35:25.199Z","phase":"Phase 1","brief_title":"A Study of TAK-102 in Adult With Previously-Treated Solid Tumors","source_id_and_acronym":"NCT04405778","lead_sponsor":"Takeda","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB102"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-27"},{"id":"fffdbde6-56a8-452b-bbea-6d93185cfd92","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928677","created_at":"2021-06-16T18:52:52.175Z","updated_at":"2024-07-02T16:35:44.506Z","phase":"Phase 1","brief_title":"A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment","source_id_and_acronym":"NCT04928677","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e codrituzumab (RG7686)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-06-28"},{"id":"76788d04-ecba-4ab1-ae56-720959e57ded","acronym":"ZZCART-003","url":"https://clinicaltrials.gov/study/NCT03198546","created_at":"2021-03-26T09:09:10.078Z","updated_at":"2024-07-02T16:35:54.565Z","phase":"Phase 1","brief_title":"GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression","source_id_and_acronym":"NCT03198546 - ZZCART-003","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TGFβ targeting CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-02-28"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"231ac021-45b1-428b-af4d-b8baa99c2e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT05123209","created_at":"2021-11-17T12:53:28.719Z","updated_at":"2024-07-02T16:36:20.577Z","phase":"Phase 1","brief_title":"Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors","source_id_and_acronym":"NCT05123209","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" PD-L1 • PD-1 • GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["PD-L1 • PD-1 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IM83"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/24/2021","start_date":" 08/24/2021","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2021-11-17"},{"id":"7999af4d-c2dc-4a34-8953-971c61fe87f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04951141","created_at":"2021-07-06T12:52:58.378Z","updated_at":"2024-07-02T16:36:28.340Z","phase":"Phase 1","brief_title":"Clinical Study of Intratumoral Injection of CAR-T Cells in the Treatment of Advanced Liver Tumors","source_id_and_acronym":"NCT04951141","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IM83"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 12/21/2023","study_completion_date":" 12/21/2023","last_update_posted":"2021-07-05"},{"id":"efe1e656-0595-47c5-99ce-031e9d0996dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02723942","created_at":"2021-01-19T11:58:36.403Z","updated_at":"2024-07-02T16:36:43.169Z","phase":"Phase 1/2","brief_title":"CAR-T Cell Immunotherapy for HCC Targeting GPC3","source_id_and_acronym":"NCT02723942","lead_sponsor":"Fuda Cancer Hospital, Guangzhou","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 08/15/2016","primary_completion_date":" 08/15/2016","study_txt":" Completion: 08/15/2016","study_completion_date":" 08/15/2016","last_update_posted":"2020-07-16"},{"id":"19a59b05-6fa7-49a1-a054-e38013d0c27a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01507168","created_at":"2021-01-18T06:20:00.730Z","updated_at":"2024-07-02T16:36:46.674Z","phase":"Phase 2","brief_title":"A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma","source_id_and_acronym":"NCT01507168","lead_sponsor":"Hoffmann-La Roche","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e codrituzumab (RG7686)"],"overall_status":"Completed","enrollment":" Enrollment 185","initiation":"Initiation: 02/02/2012","start_date":" 02/02/2012","primary_txt":" Primary completion: 08/20/2015","primary_completion_date":" 08/20/2015","study_txt":" Completion: 08/20/2015","study_completion_date":" 08/20/2015","last_update_posted":"2020-04-03"},{"id":"bb14f754-057f-42b3-a78b-090a95232262","acronym":"","url":"https://clinicaltrials.gov/study/NCT03146234","created_at":"2021-01-19T14:08:15.002Z","updated_at":"2024-07-02T16:36:56.215Z","phase":"","brief_title":"CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma","source_id_and_acronym":"NCT03146234","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CT0180"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 10/18/2018","primary_completion_date":" 10/18/2018","study_txt":" Completion: 10/18/2018","study_completion_date":" 10/18/2018","last_update_posted":"2019-08-28"},{"id":"e8843255-9af2-4b2f-8788-b94f4751a0d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02395250","created_at":"2021-01-19T10:04:57.412Z","updated_at":"2024-07-02T16:36:56.191Z","phase":"Phase 1","brief_title":"Anti-GPC3 CAR T for Treating Patients With Advanced HCC","source_id_and_acronym":"NCT02395250","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2019-08-28"},{"id":"1efc572d-4632-4234-904b-5bc55fc29127","acronym":"","url":"https://clinicaltrials.gov/study/NCT03130712","created_at":"2021-01-19T14:03:31.967Z","updated_at":"2024-07-02T16:37:23.015Z","phase":"Phase 1/2","brief_title":"A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)","source_id_and_acronym":"NCT03130712","lead_sponsor":"Shanghai GeneChem Co., Ltd.","biomarkers":" IL6 • IL2RA • GPC3 • IL10","pipe":" | ","alterations":" GPC3 expression","tags":["IL6 • IL2RA • GPC3 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 04/01/2017","start_date":" 04/01/2017","primary_txt":" Primary completion: 03/31/2018","primary_completion_date":" 03/31/2018","study_txt":" Completion: 03/31/2018","study_completion_date":" 03/31/2018","last_update_posted":"2017-04-26"}]